BMS’s Abecma Shakes Up Myeloma With Earlier-Line Approval From FDA
Executive Summary
The US FDA approved Abecma for multiple myeloma after two prior lines of therapy, while the agency was also expected to imminently decide on earlier-line approval for J&J/Legend’s Carvykti.